GFM
BCYC

GF Fund Management’s Bicycle Therapeutics BCYC Stock Holding History

GF Fund Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.79K Buy
1,032
+123
+14% +$703 ﹤0.01% 609
2025
Q4 		$6.44K Sell
909
-86
-9% -$634 ﹤0.01% 606
2025
Q3 		$7.7K Sell
995
-131
-12% -$989 ﹤0.01% 575
2025
Q2 		$7.83K Hold
1,126
– – ﹤0.01% 593
2025
Q1 		$9.56K Buy
1,126
+202
+22% +$2.38K ﹤0.01% 572
2024
Q4 		$12.9K Buy
+924
New +$19.8K ﹤0.01% 516

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GF Fund Management's BCYC Position: Q1 2026 in Review

GF Fund Management increased its Bicycle Therapeutics (BCYC) stake by 14% in Q1 2026, buying an estimated $703 and bringing the position to 1,032 shares worth $4.79K. The position accounts for ﹤0.01% of the portfolio, ranked #609.

GF Fund Management first reported a position in BCYC in Q4 2024 and has held it in 6 quarters since. The position peaked at $12.9K in Q4 2024. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • GF Fund Management held 1,032 shares of Bicycle Therapeutics worth $4.79K as of Q1 2026.
  • GF Fund Management bought 123 Bicycle Therapeutics shares in Q1 2026, an estimated $703.
  • Bicycle Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #609 holding.
  • GF Fund Management first reported a position in Bicycle Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Bicycle Therapeutics position peaked at $12.9K in Q4 2024.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.